期刊文献+

奥美拉唑肠溶胶囊人体药代动力学及生物等效性研究 被引量:1

下载PDF
导出
摘要 目的比较2种奥美拉唑肠溶胶囊在健康志愿者体内的药代动力学与生物等效性。方法20名健康志愿者,采用单剂量、随机、自身交叉对照实验设计,空腹口服奥美拉唑受试和参比制剂各40mg,用反向高效液相色谱法分别测定血药浓度,用DAS程序进行药代动力学分析,并评价两制剂的生物等效性。结果受试和参比制剂药代动力学参数AUC0→12、AUC0→∞、Cmax、tmax及t1/2分别为(3497.4±2759.1)、(3726.1±3200.5)μg/L.h-1;(3612.1±2854.6)、(3814.1±3259.1)μg/L.h-1;(1424.1±854.9)、(1421.3±951.6)μg/L;(2.23±0.50)、(2.13±0.60)h;(2.12±1.25)、(2.19±1.27)h,受试制剂的相对生物利用度为(98.2±13.2)%。经交叉实验方差分析,上述药代动力学参数无显著性差异(P>0.05)。结论两种制剂具生物等效性。
出处 《河北医科大学学报》 CAS 2007年第4期275-277,共3页 Journal of Hebei Medical University
  • 相关文献

参考文献5

二级参考文献18

  • 1楼雅卿,赵莉,张远.中国健康志愿者的奥美拉唑及其代谢物的药代动力学研究[J].中国临床药理学杂志,1994,10(1):14-21. 被引量:27
  • 2邓子煜,李雪宁,陈秋潮.HPLC测定奥美拉唑血药浓度[J].中国药学杂志,1996,31(10):608-610. 被引量:14
  • 3[1]de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22):15419-15422.
  • 4[2]Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study[J]. Clin Pharmacol Ther, 1995, 57(6):662-669.
  • 5[3]Garcia-Encina G, Farran R, Puig S, Martinez L. Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction[J]. J Pharm Biomed Anal, 1999, 21(2):371-382.
  • 6[4]Fu LQ,Huang F, Wu DZ, Guo JH. The plasma concentration of omeprazole and metabolites 5′-hydroxyomeprazole, omeprazole sulphone are determinated by HPLC[J]. Chin Pharmacol Bull(中国药理学通报), 2002, 18(3):342-344.
  • 7[5]Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19[J]. Br J Clin Pharmacol, 1995, 39(5):511-518.
  • 8[6]Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavai- lability of omeprazole after single and repeated oral administration in healthy subjects[J]. Br J Clin Pharmacol, 1990, 29(5):557-563.
  • 9[7]Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators[J]. Ther Drug Monit, 1990, 12(4):415-416.
  • 10[8]Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population[J]. J Pharmacol Exp Ther, 1992, 262(3):1195-1202.

共引文献49

同被引文献30

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部